Abstract
BackgroundThe use of stereotactic body radiotherapy (SBRT) as the primary treatment modality in clinically localized prostate cancer (PCa) is emerging. The aim of the study was to analyze the long-term results of PCa patients treated with SBRT.MethodsThis non-selected, real-life patient cohort included 213 patients with localized PCa treated with a robotic SBRT device during 2012–2015.ResultsThe median follow-up was 64 months (range, 10–85 months), and all risk-groups were represented as 47 (22.1%), 56 (26.3%) and 110 (51.6%) patients were classified into D’Amico risk stratification of low, intermediate and high-risk groups, respectively. Androgen deprivation therapy (ADT) was administered to 64.3% of the patients. At cut-off, the biochemical relapse-free survival (bRFS) was 100, 87.5 and 80.0% for patients at low, intermediate and high-risk (p = 0.004), and 92.5, 84.2 and 66.7% for patients with Gleason score ≤ 6, 7 and ≥ 8, respectively (p = 0.001). The actuarial 5-year overall survival (OS) rates were 97.9, 96.4 and 88.6% in the low, intermediate and high-risk groups, respectively, and at the cut-off, the disease-specific survival (DSS) rate of the whole cohort was high (99.1%), as only two high-risk patients died due to PCa.ConclusionOur present results of SBRT delivered with CyberKnife produced excellent long-term bRFS, OS and DSS outcomes among patients with localized PCa. We conclude that SBRT provides an efficient and convenient treatment option for patients with localized PCa, irrespective of the risk-group.
Highlights
The use of stereotactic body radiotherapy (SBRT) as the primary treatment modality in clinically localized prostate cancer (PCa) is emerging
This study focuses especially on the biochemical relapse-free survival and overall survival (OS) according to iPSA, Gleason score and D’Amico risk-stratification
The Androgen deprivation therapy (ADT) administration correlated significantly with the risk of biochemical relapse (bR), as the biochemical relapse-free survival (bRFS) was 96.1 and 81.0% among the patients treated with ADT compared to those without, respectively (p = 0.003)
Summary
The use of stereotactic body radiotherapy (SBRT) as the primary treatment modality in clinically localized prostate cancer (PCa) is emerging. The aim of the study was to analyze the long-term results of PCa patients treated with SBRT. The use of ultra-hypofractionated (≥ 5 Gy / fraction) external beam radiotherapy (EBRT) is emerging as the primary treatment modality in clinically localized prostate cancer (PCa). It can be delivered as stereotactic body radiotherapy (SBRT) by using an image guided robotic or a gantry-based device. Because of the increasing use of SBRT, there is an Vuolukka et al Radiation Oncology (2020) 15:173 urgent need to determine long-term results in terms of both efficacy and toxicity
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
